๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

โœ Scribed by A. Lipton; H. A. Harvey; R. J. Santen; A. Boucher; D. White; A. Bernath; R. Dixon; G. Richards; A. Shafik

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
341 KB
Volume
50
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A prospective randomized trial of doxoru
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer
โœ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 481 KB ๐Ÿ‘ 1 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea

A randomized trial of tamoxifen alone or
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
โœ James N. Ingle; Vera J. Suman; Carl G. Kardinal; James E. Krook; James A. Mailli ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 110 KB ๐Ÿ‘ 2 views

## BACKGROUND. Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lines and multiple endocrinologic act